Attovia Therapeutics priced its upsized IPO at $17 per share on August 4, 2026, implying a $731 million market capitalization and raising $289 million in gross proceeds, with shares set to begin trading on Nasdaq under ticker ATTO on August 5. This outcome reflects robust institutional demand for clinical-stage biotech offerings targeting immune-mediated conditions such as chronic pruritus and atopic dermatitis, supported by the company's $256 million in prior private funding and a pipeline of bispecific and trispecific candidates. The closely bunched Polymarket probabilities across the $600 million–$1 billion range capture uncertainty around first-day trading dynamics, broader biotech sector sentiment, and potential volatility tied to the absence of approved products or revenue. Key near-term catalysts include post-IPO share price performance and any early analyst coverage revisions.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於7億美元至8億美元 29%
6億美元-7億美元 27%
9億至10億美元 24%
8 億美元 - 9 億美元 19%
最新
最新
2026-08-05
低於 6 億美元
9%
6億美元-7億美元
27%
7億美元至8億美元
29%
8 億美元 - 9 億美元
19%
9億至10億美元
24%
10億美元以上
15%
2026年10月之前不會上市
9%
7億美元至8億美元 29%
6億美元-7億美元 27%
9億至10億美元 24%
8 億美元 - 9 億美元 19%
最新
最新
2026-08-05
低於 6 億美元
$3 交易量
9%
6億美元-7億美元
$0 交易量
27%
7億美元至8億美元
$0 交易量
29%
8 億美元 - 9 億美元
$0 交易量
19%
9億至10億美元
$0 交易量
24%
10億美元以上
$244 交易量
15%
2026年10月之前不會上市
$10 交易量
9%
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Attovia Therapeutics priced its upsized IPO at $17 per share on August 4, 2026, implying a $731 million market capitalization and raising $289 million in gross proceeds, with shares set to begin trading on Nasdaq under ticker ATTO on August 5. This outcome reflects robust institutional demand for clinical-stage biotech offerings targeting immune-mediated conditions such as chronic pruritus and atopic dermatitis, supported by the company's $256 million in prior private funding and a pipeline of bispecific and trispecific candidates. The closely bunched Polymarket probabilities across the $600 million–$1 billion range capture uncertainty around first-day trading dynamics, broader biotech sector sentiment, and potential volatility tied to the absence of approved products or revenue. Key near-term catalysts include post-IPO share price performance and any early analyst coverage revisions.
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
市場開放時間： Aug 4, 2026, 9:51 PM ET
交易量
$257結束日期
2026-08-05市場開放時間
Aug 4, 2026, 9:51 PM ETResolver
0x69c47De9D...This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Attovia Therapeutics priced its upsized IPO at $17 per share on August 4, 2026, implying a $731 million market capitalization and raising $289 million in gross proceeds, with shares set to begin trading on Nasdaq under ticker ATTO on August 5. This outcome reflects robust institutional demand for clinical-stage biotech offerings targeting immune-mediated conditions such as chronic pruritus and atopic dermatitis, supported by the company's $256 million in prior private funding and a pipeline of bispecific and trispecific candidates. The closely bunched Polymarket probabilities across the $600 million–$1 billion range capture uncertainty around first-day trading dynamics, broader biotech sector sentiment, and potential volatility tied to the absence of approved products or revenue. Key near-term catalysts include post-IPO share price performance and any early analyst coverage revisions.
This market will resolve based on Attovia Therapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 5 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
交易量
$257結束日期
2026-08-05市場開放時間
Aug 4, 2026, 9:51 PM ETResolver
0x69c47De9D...Attovia Therapeutics priced its upsized IPO at $17 per share on August 4, 2026, implying a $731 million market capitalization and raising $289 million in gross proceeds, with shares set to begin trading on Nasdaq under ticker ATTO on August 5. This outcome reflects robust institutional demand for clinical-stage biotech offerings targeting immune-mediated conditions such as chronic pruritus and atopic dermatitis, supported by the company's $256 million in prior private funding and a pipeline of bispecific and trispecific candidates. The closely bunched Polymarket probabilities across the $600 million–$1 billion range capture uncertainty around first-day trading dynamics, broader biotech sector sentiment, and potential volatility tied to the absence of approved products or revenue. Key near-term catalysts include post-IPO share price performance and any early analyst coverage revisions.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions